Why Türkiye
Why choose Türkiye for cancer care?
Turkish medical treatment and healthcare sector is one of the best in the world.
Five reasons to choose Türkiye
1. Advanced oncology infrastructure
Türkiye has invested substantially in modern hospitals, specialist oncology services, radiotherapy, nuclear medicine, advanced imaging and medical technologies. The Turkish Ministry of Health maintains a dedicated system of healthcare providers authorized to treat international patients.
2. Access to specialized multidisciplinary care
Major Turkish hospitals provide medical oncology, radiation oncology, oncological surgery and related specialties within large tertiary-care institutions. This allows complex cancer cases to be evaluated across different specialties rather than by a single physician alone.
3. A regulated international-patient system
The Ministry of Health authorizes healthcare facilities and intermediary organizations providing international health-tourism services. Requirements are being strengthened further: under the current framework, relevant hospitals and medical centers must meet TÜSKA accreditation requirements by the end of 2026.
4. Competitive treatment costs
Türkiye's official international-health organization identifies affordability relative to Europe as one of the country's advantages for international patients, alongside qualified medical personnel and modern medical equipment. The exact saving varies considerably by cancer, hospital, medicine and treatment protocol.
5. Istanbul is highly accessible for international patients
Türkiye's location and extensive international air connectivity have helped it develop a substantial infrastructure around international healthcare. USHAŞ specifically identifies geographic accessibility and international flight connectivity as advantages of Türkiye's health-tourism sector.
Advanced oncology
Advanced and specialized oncology applications in Türkiye
Diagnostic and treatment methods, and their main areas of use.
- Ga-68 PSMA PET/CT
- Assessing the spread of prostate cancer and determining eligibility for PSMA-targeted therapies
- Lu-177 PSMA
- Targeted radionuclide therapy for eligible patients with advanced/metastatic prostate cancer
- Ac-225 PSMA
- Targeted alpha therapy in selected cases of advanced prostate cancer
- Ga-68 DOTATATE PET/CT
- Assessing neuroendocrine tumors and determining eligibility for targeted radionuclide therapy
- Lu-177 DOTATATE (PRRT)
- Targeted radionuclide therapy for eligible neuroendocrine tumors
- Ac-225 DOTATATE
- Alpha radionuclide therapy in selected neuroendocrine tumor cases
- TrueBeam / stereotactic radiotherapy
- Delivering radiation to the tumor with high precision
- CyberKnife / Gamma Knife
- Stereotactic radiosurgery and radiotherapy for selected tumors
- Da Vinci robotic oncological surgery
- Minimally invasive surgery, particularly for selected urological and other cancers
- Targeted / personalized therapies
- Treatments selected according to the biological and molecular characteristics of the tumor
*Important notice: The information provided here is for general information purposes only and does not constitute medical advice, diagnosis or a treatment recommendation. Not every diagnostic or treatment method may be suitable for every patient. A patient's eligibility for a particular diagnostic or treatment method is determined by the relevant specialist physicians, based on an evaluation of their medical history, the type and stage of the disease, previous treatments, imaging and laboratory results, and other clinical findings. The treatment options presented and their availability may vary depending on the hospital, the physician and the patient's clinical condition.
*Hatira Ozel does not diagnose patients or make treatment decisions; we provide patients with access to appropriate specialist physicians and healthcare institutions, and coordinate the case evaluation process and the treatment journey.
Tell us about your case
Your case is addressed within 2 days at most.